@icyops@AndreassonCalle@himshouse Please do not use trust pilot as a data source for investment decisions π Appreciate you painting the picture Icy π―
@amitisinvesting Amit bought HIMS. It's a starter position but I am currently making him a video on the actual thesis on why HIMS will change Healthcare. That starter position will grow π Let me know when you want to hear the thesis!
@DataDInvesting 1000%. People complain about no moat, but who are they competing against? LILY and novo will not have a successful stand alone platform. HIMS is netflix for prescription medication. People don't realize how big the acquisitions they just had are for future verticals.
@himshouse The usually suspects. BofA and Citi should really be investigated. Do they not have to state their organization is short when giving fraudulent ratings?
$BofA just issued their 4th "sell" rating on $HIMS in the past month. To be fair, I did warn you to close out your short position. Now you just look desperate
Watch $BofA reiterate their $22 sell rating on HIMS in back to back days. They have already reiterated it 4 times since the initial rating was given. BofA is a massively short HIMS and they are getting a bit desperate... and it shows.
$hims The LILY news will have little to no impact on HIMS business model. HIMS owns the patient relationship. LILY just announced a blockbuster hit movie and HIMS is netflix. News flash, everything ends up on netflix.
@himshouse What an absolute joke of a institution. They have reiterated their sell 3 times in the past month and a half... tell me your short without telling me your short. Cannot wait to crush BofA